Role of polyunsaturated fatty acids and fatty acid binding protein in the pathogenesis of schizophrenia

Current Pharmaceutical Design

Volumn 17, Issue 2, 2011, Pages 168-175

  Maekawa, Motoko ^a   Owada, Yuji ^b   Yoshikawa, Takeo ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endophenotype; FABP7; Gene expression; Genetic association; Postmortem brain; Prepulse inhibition

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FATTY ACID; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; FATTY ACID BINDING PROTEIN 5; FATTY ACID BINDING PROTEIN 7; FOLIC ACID; ICOSAPENTAENOIC ACID; LAURIC ACID; LINOLEIC ACID; LINOLENIC ACID; MONOUNSATURATED FATTY ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; OLEIC ACID; PALMITIC ACID; POLYUNSATURATED FATTY ACID; STEARIC ACID; TRANSCRIPTION FACTOR PAX6; UNCLASSIFIED DRUG;

ARTICLE; BRAIN DEVELOPMENT; CELL MOTILITY; CHEMICAL BOND; CONCEPT ANALYSIS; DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE; FATTY ACID DESATURATION; FATTY ACID METABOLISM; GENE EXPRESSION; HUMAN; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, UNSATURATED; FEMALE; FETAL DEVELOPMENT; HUMANS; MALE; MALNUTRITION; MOLECULAR TARGETED THERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; RATS; SCHIZOPHRENIA; STARVATION; UP-REGULATION;

EID: 79953330007     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795049615     Document Type: Article

References (67)

1. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005; 10: 434-49.
2. McNeil TF, Cantor-Graae E, Ismail B. Obstetric complications and congenital malformation in schizophrenia. Brain Res Brain Res Rev 2000; 31: 166-78.
3. Smith DW. Recognizable patterns of human malformation., WB Saunders: Philadelphia 1970.
4. O'Callaghan E, Buckley P, Madigan C, et al. The relationship of minor physical anomalies and other putative indices of developmental disturbance in schizophrenia to abnormalities of cerebral structure on magnetic resonance imaging. Biological Psychiatry 1995; 38: 516-24.
5. Toyota T, Yoshitsugu K, Ebihara M, et al. Association between schizophrenia with ocular misalignment and polyalanine length variation in PMX2B. Hum Mol Genet 2004; 13: 551-61.
6. Yoshitsugu K, Yamada K, Toyota T, et al. A novel scale including strabismus and 'cuspidal ear' for distinguishing schizophrenia patients from controls using minor physical anomalies. Psychiatry Res 2006; 145: 249-58.
7. Susser ES, Lin SP. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. Arch Gen Psychiatry 1992; 49: 983-8.
8. St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA 2005; 294: 557-62.
9. Richardson AJ. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids 2004; 39: 1215-22.
10. Neugebauer R, Hoek HW, Susser E. Prenatal exposure to wartime famine and development of antisocial personality disorder in early adulthood. JAMA 1999; 282: 455-62.
11. Roseboom TJ, van der Meulen JH, Ravelli AC, Osmond C, Barker DJ, Bleker OP. Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview. Twin Res 2001; 4: 293-8.
12. Silveira PP, Portella AK, Goldani MZ, Barbieri MA. Developmental origins of health and disease (DOHaD). J Pediatr (Rio J) 2007; 83: 494-504.
13. st century. Perspect Biol Med 1998; 42: 44-74.
14. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 1989; 2: 577-80.
15. Gluckman PD, Hanson MA. Developmental origins of disease paradigm: a mechanistic and evolutionary perspective. Pediatr Res 2004; 56: 311-7.
16. Heijmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A 2008; 105: 17046-9.
17. Marszalek JR, Lodish HF. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish aregood for you. Annu Rev Cell Dev Biol 2005; 21: 633-57.
18. McNamara RK, Ostrander M, Abplanalp W, Richtand NM, Benoit SC, Clegg DJ. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 237-57.
19. Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 2005; 45: 559-79.
20. Grossfield A, Feller SE, Pitman MC. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc Natl Acad Sci U S A 2006; 103: 4888-93.
21. Kitajka K, Sinclair AJ, Weisinger RS, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci U S A 2004; 101: 10931-6.
22. Schroeder F, Petrescu AD, Huang H, et al. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 2008; 43: 1-17.
23. Purasiri P, McKechnie A, Heys SD, Eremin O. Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. Immunology 1997; 92: 166-72.
24. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277: 8755-8.
25. Venkatraman J, Meksawan K. Effects of dietary omega3 and omega6 lipids and vitamin E on chemokine levels in autoimmune-prone MRL/MpJ-lpr/lpr mice. J Nutr Biochem 2002; 13: 479.
26. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007; 6: 21.
27. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78: 587-91.
28. Mellor JE, Laugharne JD, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res 1995; 18: 85-6.
29. Peet M. Nutrition and schizophrenia: an epidemiological and clinical perspective. Nutr Health 2003; 17: 211-9.
30. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP.Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003; 62: 195-204.
31. Arvindakshan M, Sitasawad S, Debsikdar V, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003; 53: 56-64.
32. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-8.
33. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243-51.
34. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18.
35. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 393-9.
36. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never- medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002; 58: 1-10.
37. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004; 30: 901-11.
38. Anderson GJ, Neuringer M, Lin DS, Connor WE. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? ffects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr Res 2005; 58: 865-72.
39. Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res 1990; 31: 237-47.
40. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991; 30: 795-805.
41. Yao JK, Leonard S, Reddy RD. Membrane phospholipids abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000; 42: 7-17.
42. Landen M, Davidsson P, Gottfries CG, Mansson JE, Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr Res 2002; 55: 83-8.
43. McNamara RK, Jandacek R, Rider T, et al. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr Res 2007; 91: 37-50.
44. Watanabe A, Toyota T, Owada Y, et al. Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol 2007; 5: e297.
45. Graham FK. Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 1975; 12: 238- 48.
46. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001; 156: 234-58.
47. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
48. Owada Y, Abdelwahab SA, Kitanaka N, et al. Altered emotional behavioral responses in mice lacking brain-type fatty acid-binding protein gene. Eur J Neurosci 2006; 24: 175-87.
49. Boneva NB, Kaplamadzhiev DB, Sahara S, et al. Expression of fatty acid-binding proteins in adult hippocampal neurogenic niche of postischemic monkeys. Hippocampus 2011; 21: 162-71.
50. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002; 88: 411-20.
51. Giltay EJ, Gooren LJ, Toorians AW, Katan MB, Zock PL. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am J Clin Nutr 2004; 80: 1167-74.
52. Huber TJ, Tettenborn C, Leifke E, Emrich HM. Sex hormones in psychotic men. Psychoneuroendocrinology 2005; 30: 111-4.
53. Maekawa M, Takashima N, Matsumata M, et al. Arachidonic acid drives postnatal neurogenesis and elicits a beneficial effect on prepulse inhibition, a biological trait of psychiatric illnesses. PLoS One 2009; 4: e5085.
54. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo- controlled trial. Arch Gen Psychiatry 2010; 67: 146-54.
55. Maekawa M, Iwayama Y, Watanabe, et al. Excessive ingestion of long-chain polyunsaturated fatty acids during developmental stage causes strain- and sex-dependent eye abnormalities in mice. Biochem Biophys Res Commun 2010; 402: 431-37.
56. Owada Y. Fatty acid binding protein: localization and functional significance in the brain. Tohoku J Exp Med 2008; 214: 213-20.
57. Liu RZ, Mita R, Beaulieu M, Gao Z, Godbout R. Fatty acid binding proteins in brain development and disease. Int J Dev Biol 2010; 54: 1229-39.
58. Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 2008; 28: 73-95.
59. Hanhoff T, Lucke C, Spener F. Insights into binding of fatty acids by fatty acid binding proteins. Mol Cell Biochem 2002; 239: 45-54.
60. Haunerland NH, Spener F. Fatty acid-binding proteins-insights from genetic manipulations. Prog Lipid Res 2004; 43: 328-49.
61. Owada Y, Yoshimoto T, Kondo H. Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains. J Chem Neuroanat 1996; 12: 113-22.
62. Balendiran GK, Schnutgen F, Scapin G, et al. Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem 2000; 275: 27045-54.
63. Murphy EJ, Owada Y, Kitanaka N, Kondo H, Glatz JF. Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry 2005; 44: 6350-60.
64. Liu JW, Almaguel FG, Bu L, De Leon DD, De Leon M. Expression of E-FABP in PC12 cells increases neurite extension during differentiation: involvement of n-3 and n-6 fatty acids. J Neurochem 2008; 106: 2015-29.
65. Hohoff C, Borchers T, Rustow B, Spener F, van Tilbeurgh H. Expression, purification, and crystal structure determination of recombinant human epidermal-type fatty acid binding protein. Biochemistry 1999; 38: 12229-39.
66. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006; 3: CD001257.
67. Nathanielsz PW. Animal models that elucidate basic principles of the developmental origins of adult diseases. ILAR J 2006; 47: 73-82.